Open access peer-reviewed chapter

Perinatal Immune Activation and Risk of Autism

Written By

Theoharis Theoharides, Asimenia Angelidou, Konstantinos-Dionysios Alysandratos, Shahrzad Asadi, Konstantinos Francis, Lefteris Lykouras and Dimitrios Kalogeromitros

Submitted: October 20th, 2010 Reviewed: May 9th, 2011 Published: August 17th, 2011

DOI: 10.5772/17436

Chapter metrics overview

2,231 Chapter Downloads

View Full Metrics

1. Introduction

He could fit in the palms of both hands, seemed to look at you beseechingly while you rushed to thread a vein and snake a tube down a tiny nostril of this 24 week preemie. Already exposed to the prenatal stress that culminated in premature delivery, he has been further exposed to the stress associated with the separation from his mother and multiple medical interventions. Like other premature babies, he is more vulnerable to invasive infections from bacteria and viruses; moreover, the delayed development of his gut-blood-brain barriers could expose him to potential neurotoxins.

Such infants are up to 4 times more likely to develop autism. If their mothers had allergies, mastocytosis or an autoimmune disease, this risk almost doubles.

Autism Spectrum Disorders (ASD) are pervasive developmental disorders that include Autistic Disorder and Asperger’s Disorder, although Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS) is frequently included (Johnson & Myers, 2007). ASD are characterized by variable deficits in social skills, stereotypic behaviors, and a wide range of behavioral and learning problems. ASD manifest during early childhood and at least 30% present with sudden clinical regression of development around 3 years of age (Matson J.L. & Kozlowski A.M., 2010; Zappella, 2010). Over the last 20 years, there has been an impressive rise in ASD with current prevalence estimates of 1/100 children (Fombonne, 2009; Kogan et al., 2009).

In the majority of cases, the cause of ASD is unknown (Levy et al., 2009). Some autism susceptibility genes have been identified (Weiss et al., 2009), but gene interactions with environmental factors are increasingly suspected (Deth et al., 2008; Herbert, 2010). Recent reviews have focused mostly on genomic screens that suggest there are multiple gene interactions in autism; however no gene abnormality alone can explain the apparent increase in ASD prevalence (Durkin et al., 2010; Herbert, 2010; Miles, 2011). Increasing evidence suggests that there are different ASD endophenotypes, even within the ASD spectrum (Palmieri & Persico, 2010).

Intrauterine conditions in combination with external environmental triggers or specific genotypes, may lead to developmental disturbances. Indeed, an epidemiologic study, nested within a cohort of 698 autistic children in Denmark, concluded that prenatal environmental factors and parental psychopathology are associated with the risk of autism and these factors seem to act independently (Larsson et al., 2005). It is also recognized that tuberous sclerosis, a neurocutaneous disorder, involves autistic symptoms in approximately 40-45% of cases (Smalley, 1998). It has been proposed that this partial penetrance may be the result of an interaction between gene mutations and environmental factors, such as gestational immune activation (Ehninger et al., 2010). An early environmental insult, such as prenatal infection could cause long-term changes in neural function by altering epigenetic programming. Studies on rodents suggest that during early development, environmental signals can activate intracellular pathways, leading to epigenetic changes and consequently changes in neural function (Zhang & Meaney, 2010). In fact, variations in early maternal care affect stress responses in the offspring by altering the methylation status of the glucocorticoid receptor gene promoter (Weaver et al., 2004).

Advertisement

2. The role of prematurity

Premature births (delivery prior to 37 weeks gestation) currently account for 12.7% of all births in the United States, a rise of approximately 20% in the past two decades (MacDorman et al., 2010). Although infants less than 28 weeks gestation are at the highest risk for long-term neurologic problems, infants born between 32 and 36 weeks are increasingly recognized to be at risk for neurologic injury, such as leukomalacia and grey matter damage (Adams-Chapman, 2006; Argyropoulou, 2010; Okumura et al., 2010; Volpe, 2009). Clinical, epidemiological and experimental studies have revealed that key factors, such as inflammation and oxidative stress contribute considerably to white- and grey-matter injury in premature infants, whose brains are particularly susceptible to damage (Kaindl et al., 2009). In infants surviving premature birth, cerebellar hemorrhagic injury is also associated with a high prevalence of neurodevelopmental disabilities (Limperopoulos et al., 2007). The resulting long-term neurologic complications may include learning difficulties, behavioral and socio-emotional concerns, and poor general health outcomes. These vulnerable near-term (late preterm) infants make up the greatest number of premature births and account for the significant increase in the rate of prematurity in the recent years (Martin, 2011). Although the etiology of premature delivery is often unknown, chronic in uteroinflammation or infection are well-described conditions that lead to preterm labor and birth (Dubicke et al., 2010; Snegovskikh et al., 2009; Thaxton et al., 2010). Inflammation itself has been strongly associated with adverse neurodevelopmental outcomes in premature infants (Lin et al., 2010; Rovira et al., 2011). An additional 5-8% of deliveries are complicated by pre-eclampsia or gestational diabetes, which may lead to placental insufficiency, abnormal growth, and postnatal metabolic imbalance. Excessive production of cortocotropin releasing hormone (CRH) has also been linked to preterm labour (Campbell et al., 1987; Warren et al., 1992). A number of cytokines are known to cause in vitro secretion of CRH from cultured placental trophoblasts, including IL-1 and IL-6 (Petraglia et al., 1990). In turn, CRH stimulates release of IL-6 from peripheral blood mononuclear cells, which infiltrate the fetal membranes and the placenta in increasing numbers during intrauterine infection (Angioni et al., 1993).

Recent reports suggest a potential association between preterm birth and autism. In particular, one retrospective study investigated preterm children born in Atlanta, GA (1981-93) who survived to three years of age, and identified rates of autism through the Metropolitan Atlanta Developmental Disabilities Surveillance Program. Preterm birth prior to 33 weeks gestation was associated with a two-fold higher risk of autism in all infants (Limperopoulos et al., 2008). Interestingly, this study reported a gender-specific, four-fold increased risk for autism accompanied by mental retardation in preterm girls with low birth weight (LBW) (<2,500 g at birth). Another study performed a prospective follow-up assessment on 91 ex-preterm very low birth weight (VLBW) infants (<1,500 g at birth) at the mean age of 22 months and found 26% of these children to have a positive Modified Checklist for Autism in Toddlers (M-CHAT) test (Kinney et al., 2008). A more recent study found that 21% of infants (212/988) born before 28 weeks of gestation screened positive using M-CHAT (Kuban et al., 2009) as compared to 5.7% of healthy children 16-30 months old (Kleinman et al., 2008). Much higher rates of positive testing on M-CHAT were found in premature children with motor or sensory impairment (Kuban et al., 2009). It should be noted, however, that a positive CHAT test must be confirmed with more specific diagnostic tools, such as the Autism Diagnostic Observation Schedule-Generic (ADOS-G, a patient observational tool) or the Autism Diagnostic Interview-Revised (ADI-R, a parent interview tool) which provide a more reliable diagnosis for ASD. A prospective study of all births less than 26 weeks gestation in 1995 in the United Kingdom and Ireland concluded that ex-preterm children are at increased risk for ASD in middle childhood, compared with their term-born classmates, after psychiatric, clinical, IQ and SCQ (Social Communication Questionnaire) evaluations (Johnson et al., 2010).

A cohort of 164 families with autistic children (Brimacombe et al., 2007) concluded that the increased risk of autistic disorders related to prematurity is primarily attributed to perinatal complications that occur more commonly among preterm infants, results also confirmed in a Swedish population-based case-control study (Buchmayer et al., 2009). A meta-analysis on prenatal risk factors for autism argued that evidence is insufficient to implicate individual prenatal factors in autism etiology, because many of the studies examined all available prenatal data using designs with methodological weaknesses, so that significant associations may have been observed by chance after multiple testing (Gardener et al., 2009). Findings from population-based studies suggest that suboptimal birth conditions are not independent risk factors for infantile autism, but rather clusters of them increase the risk of ASD (Maimburg & Vaeth, 2006). Finally, a more recent cohort study on infants born in Canada between 1990-2002 concluded that perinatal risk factors including prenatal, obstetrical and neonatal complications, have a lesser overall effect on autistic outcomes among the genetically susceptible pediatric population, compared to children with low genetic susceptibility (Dodds et al., 2010). Reviews of studies evaluating neurobehavioral outcomes following preterm birth reveal a “preterm behavioral phenotype” characterized by symptoms of inattention, anxiety and social difficulties (Johnson & Marlow, 2011; Limperopoulos, 2009).

Advertisement

3. Maternal autoimmune diseases

The relationship between ASD and familial autoimmunity has long been recognized (Money et al., 1971), and has been supported by at least three large population-based studies discussed below; these studies utilized medical records and physician data to determine autoimmunity in families of ASD and typically-developing children.

One case-control study nested within a cohort of infants born in California between 1995-1999, examined the association of “immune-related conditions” with ASD using health records and reported that prevalence of maternal psoriasis, asthma, hay fever and atopic dermatitis during the second trimester of pregnancy correlated with over two-fold elevated risk of ASD in their children (Croen et al., 2005). The second cohort consisted of the pediatric population born in Denmark from 1993 through 2004 (n=689,196), in which 3,325 children were diagnosed with ASD including 1,089 cases of infantile autism. The study confirmed an association between family history of type 1 diabetes and infantile autism, as well as rheumatoid arthritis and ASD; it was also the first to show a significant association between maternal celiac disease and ASD (Atladottir et al., 2009). A significant association between parental rheumatic fever and ASD, as well as several significant correlations between maternal autoimmune diseases and ASD were investigated across 3 Swedish registries by means of a case-control study (n=1,227 ASD cases matched with 25 controls each) (Keil et al., 2010). Auto-antibodies against brain proteins have been reported in a number of mothers with children who developed autism (Croen et al., 2008). A possible explanation for the link between maternal immune dysregulation and ASD would be the transfer of maternal autoantibodies to the developing fetus during pregnancy (Braunschweig et al., 2008; Croen et al., 2008; Singer et al., 2008; Zimmerman et al., 2007), resulting in abnormal neurodevelopment. This phenomenon was manifested in the offsprings of pregnant mice after their transfection with human systemic lupus erythematosus autoantibodies (Lee et al., 2009). A preliminary report also indicated that mothers with a diagnosis of mastocytosis during pregnancy had a high chance of having one or more children with autism (Theoharides, 2009).

Results from animal modeling studies clearly indicate that maternal immune activation (MIA) can cause both acute and lasting changes in behavior and CNS structure and function in the offspring (Boksa, 2010). Administration of bacterial lipopolysaccharide (LPS), a cell wall component from Gram-negative bacteria, activates Toll-like receptor-4 (TLR-4) on immune cells leading to synthesis and release of TNF (Varadaradjalou et al., 2003), IL-1 and IL-6 (Supajatura et al., 2002). It was recently shown that IL-1 receptor antagonism prevented neurodevelopmental anomalies in pregnant rats after systemic end-of-gestation exposure to LPS (Girard et al., 2010). In addition to its direct detrimental effect on the placenta and fetal brain tissue, IL-1 induces selective release of IL-6 from mast cells (Kandere-Grzybowska et al., 2003). IL-6 appears critical for fetal brain development and social behavior development, as demonstrated in a poly(I:C) mouse model for MIA, where co-administration of anti-IL-6 antibody prevented the social deficits and associated gene expression changes in the brain of the offspring (Smith et al., 2007).

However, human studies investigating the role of prenatal infection in the pathogenesis of autism are limited, and mostly focused on viral infections (Chess, 1977; Libbey et al., 2005; Wilkerson et al., 2002). A recent nationwide study in Denmark including children born from 1980 through 2005 points to an increased risk for ASD after maternal viral infection in the first trimester of pregnancy (adjusted hazard ratio = 2.98; CI: 1.29-7.15) or maternal bacterial infection in the second trimester of pregnancy (adjusted hazard ratio = 1.42; CI: 1.08-1.87) (Atladottir et al., 2010). Moreover, a number of rotaviruses have been isolated from asymptomatic neonates (Dunn et al., 1993). Viral double-stranded RNA like poly(I:C) induces release of TNF and IL-6 without degranulation from mast cells through viral TLR-3 (Kulka et al., 2004).

Advertisement

4. Autoimmunity in ASD children

A recent study implied the presence of an endophenotype with complex immune dysfunction both in autistic children and their non-autistic siblings (Saresella et al., 2009). Brain-specific auto-antibodies are present in the plasma of many ASD individuals (Cabanlit et al., 2007; Singh et al., 1997; Singh & Rivas, 2004). Such auto-antibodies suggest a loss of self-tolerance to neural antigens during early neurodevelopment, but their precise role in autism remains unknown (Enstrom et al., 2009; Mostafa et al., 2008; Mostafa & Kitchener, 2009; Wills et al., 2007). They may indicate disruption of the blood-brain barrier (BBB), at least in a subgroup of patients. The presence of an auto-inflammatory response is also supported by the detection of certain inflammation markers. For instance, TNF was high in the cerebrospinal fluid (CSF) (Chez et al., 2007), and IL-6 gene expression was increased in the brain (Li et al., 2009) of autistic patients. CSF and microglia of ASD patients had high levels of macrophage chemoattractant protein-1 (MCP-1) (Vargas et al., 2005), which is also a potent chemoattractant for mast cells (Conti et al., 1997). In contrast, ASD plasma levels of transforming growth factor-beta1 (TGF-β1) were low (Ashwood et al., 2008), which is important in view of the fact that TGF-β1 inhibits mast cell function (Gebhardt et al., 2005). Many children with ASD also report gastrointestinal symptoms (Buie et al., 2010). In a few studies, examination of intestinal biopsies from children with regressive autism reveals features of an autoimmune mucosal pathology, that is not seen in other conditions or inflammatory bowel diseases (Ashwood et al., 2003; Torrente et al., 2002).

Many of the epidemiologic, biochemical and pathologic findings could be explained through activation of mast cells, immune cells important in both innate and acquired immunity (Galli et al., 2005), as well as in inflammation (Theoharides & Kalogeromitros, 2006). Mast cells are well-known for their leading role in allergic reactions, during which they are stimulated by IgE binding to high-affinity receptors (FcεRI), aggregation of which leads to degranulation and secretion of numerous pre-stored and newly-synthesized mediators, including IL-6 and TNF (Blank & Rivera, 2004; Kraft & Kinet, 2007; Schroeder et al., 1995; Schwartz, 1987; Serafin & Austen, 1987; Stone et al., 2010; Torigoe et al., 1997). In addition to IgE, many substances originating in the environment, the intestine or the brain can trigger mast cell activation (Theoharides et al., 2011). These include non-allergic environmental, infectious, neurohormonal and oxidative stress-related triggers, involving release of mediators selectively, without degranulation (Theoharides et al., 2007b). For instance, LPS activates TLR-4 on mast cells and induces selective release of TNF (Varadaradjalou et al., 2003), while IL-1 induces selective release of IL-6 (Kandere-Grzybowska et al., 2003).

Environmental toxins have been implicated in developmental neurotoxicity (Grandjean & Landrigan, 2006) and also in mast cell activation. In particular, polychlorinated biphenyl (PCB) (Hertz-Picciotto et al., 2008) and mercury (Young et al., 2008) have been associated with ASD, and both also activate mast cells (Asadi et al., 2010; Kempuraj et al., 2010; Kwon et al., 2002). Other mast cell triggers include bacterial and viral antigens, as well as peptides such as neurotensin (NT), which we reported to be increased in serum of young children with autism (Angelidou et al., 2010), and to induce mast cell release of extracellular mitochondrial DNA, which was also increased in the serum of these ASD patients (Zhang et al., 2010). This finding may be in addition to mitochondrial dysfunction reported in ASD (Giulivi et al., 2010; Palmieri & Persico, 2010). Given the fact that NT activates mast cells (Theoharides et al., 2004) and abundant NT is located in the gut (Castagliuolo et al., 1996), its elevated levels might lead to gut dysfunction in a cohort of autistic patients. NT also augments the action of CRH, which stimulates selective release of vascular endothelial growth factor (VEGF) (Cao et al., 2005). In fact, CRH acts synergistically with NT to increase vascular permeability (Donelan et al., 2006).

Mast cell-derived cytokines can also increase BBB permeability (Abbott, 2000; Theoharides & Konstantinidou, 2007). BBB disruption has been documented in brain inflammatory diseases, such as multiple sclerosis, where it precedesany pathological or clinical symptoms (Minagar & Alexander, 2003; Soon et al., 2007; Stone et al., 1995). We speculate that perinatal mast cell activation, in response to allergic or non-immune triggers, could disrupt the gut-blood-brain barriers (Theoharides & Doyle, 2008) and permit neurotoxic molecules to enter the brain and result in brain inflammation, thus contributing to ASD pathogenesis (Fig. 1) (Theoharides et al., 2008). It is intriguing that mast cell-derived IL-9 induces intestinal permeability and predisposes to oral antigen hypersensitivity in children (Forbes et al., 2008), while it also exacerbates newborn brain toxic lesions (Dommergues et al., 2000). Moreover, IL-33 can synergize with SP (Theoharides et al., 2010) and SCF (Drube et al., 2010) in stimulating mast cell TNF release, while it also activates glial cells to secrete pro-inflammatory cytokines (Yasuoka et al., 2011). The possible involvement of mast cells (Theoharides et al., 2011) in ASD is also supported by the fact that many children with ASD report “allergic-like” symptoms (Angelidou et al., 2011).

Advertisement

5. Perinatal stress

Mast cells have been implicated in inflammatory conditions that worsen by stress (Theoharides & Cochrane, 2004) and in regulating BBB permeability (Esposito et al., 2002). It was shown that early life stress due to maternal separation resulted in an altered brain-gut axis; it was sufficient to cause an increase in the blood concentrations of pro-inflammatory cytokines after a challenge with LPS, and also an increase in plasma corticosterone (O'Mahony et al., 2009). The timing of prenatal stressors was investigated in a case-control study, recording mothers’ reports on exposure to stressors during each 4-week block of pregnancy. A higher incidence of stressors at 21-32 weeks gestation was found in autism, in consistency with the embryological age at which pathological cerebellar changes in autism are seen (Beversdorf et al., 2005).

We propose that prenatal or perinatal stress may contribute to the development of ASD through excessive release of CRH. CRH is typically secreted from the hypothalamus, but it can also be secreted from the skin (Slominski et al., 2006) and nerve endings (Skofitsch et al., 1985), where it exerts pro-inflammatory effects (Chrousos, 1995; Slominski et al., 2001; Theoharides et al., 2008). CRH can also be released from immune cells (Karalis et al., 1997)

and mast cells (Kempuraj et al., 2004). In fact, CRH released from hair follicles can trigger mast cell proliferation (Ito et al., 2010). This form of tissue CRH sometimes called “immune CRH” may have an immunomodulatory role as an autocrine/paracrine mediator of inflammation during reproduction (Kalantaridou et al., 2007). One of the early effects of immune CRH is the activation of mast cells and the release of several pro-inflammatory cytokines (Theoharides et al., 2004). CRH was increased in the serum of mothers who delivered preterm babies and correlated with their level of anxiety during that period of pregnancy (Makrigiannakis et al., 2007). Maternal serum CRH can cross the placenta, and potentially high amounts of CRH could be produced by the placenta itself in response to external or intrauterine stress (Grammatopoulos, 2008; Torricelli et al., 2011). CRH can then disrupt the BBB (Theoharides & Konstantinidou, 2007), which appears to be compromised in ASD patients, as indicated by the presence of autoantibodies against encephalogenic peptides (Cabanlit et al., 2007; Goines & Van de Water J., 2010; Singer et al., 2006; Vojdani et al., 2002; Wills et al., 2008). BBB disruption due to stress is dependent on both CRH

Figure 1.

Diagrammatic depiction of how perinatal immune activation may contribute to brain inflammation and autism. CRH, corticotropin-releasing hormone; IL, interleukin; LPS, lipopolysaccharide; MCP-1, macrophage chemoattractant protein-1; mtDNA, mitochondrial DNA; NT, neurotensin; PCB, polychlorinated biphenyl; poly(IC),polyinosinic:polycytidylic acid; ROS, reactive oxygen species; SP, substance P; TGFβ1, transforming growth factor-beta1; TNF, tumor necrosis factor

(Esposito et al., 2002) and mast cells (Esposito et al., 2001) and is associated with high serum IL-6 that is also mast cell-dependent (Theoharides & Konstantinidou, 2007).

The effect of CRH may be relevant to the behavioral manifestations of ASD. ASD patients had high anxiety levels and were unable to handle stress appropriately (Gillott & Standen, 2007). Evening cortisol levels positively correlated to daily stressors in children with autism (Corbett et al., 2009). Moreover, increase in age of autistic children correlated with increased cortisol levels during social interaction stress (Corbett et al., 2010). CRH has also been shown to increase intestinal permeability of human colonic biopsies, while maternal separation stress and CRH are associated with a dysfunctional mucosal barrier in rodents (Soderholm et al., 2002). A short period of restraint (Chandler et al., 2002) or maternal deprivation stress (Teunis et al., 2002) also increased the severity of experimental autoimmune encephalomyelitis.

The presence of maternal stress may explain why children born within a year of the first child that developed autism had a much higher chance of developing autism than if they were born two years later (Cheslack-Postava et al., 2011). Increased circulating CRH, directly or through immune cell release of other inflammatory and vasoactive molecules, can disrupt the gut-blood-brain barriers during gestation and/or infancy and permit absorption of intestinal-derived inflammatory and neurosensitizing mediators.

Advertisement

6. Other perinatal risk factors

High weight gain in pregnancy has been considered an independent risk factor for autism in the offspring (Stein et al., 2006). Even though a clear mechanism is lacking, leptin is suspected to play a major role. Obese subjects have higher leptin levels than normal weight subjects (Considine et al., 1996; Dardeno et al., 2010). Additionally, it has been suggested that elevated plasma leptin levels during pregnancy are indicative of placental dysfunction (Hauguel-de et al., 2006). Placental insufficiency, possibly associated with anoxia, may also contribute to autism in the offspring (Glasson et al., 2004).

Elevated plasma leptin levels were reported in children with regressive autism (n=37), compared with typically-developing controls (n=50) (Ashwood et al., 2007). One group also measured the variation of circulating leptin at baseline and after one year of follow-up in 35 patients with “classic autism” (according to DSM-IV criteria) aged 14.1±5.4 years old. The authors reported significantly higher leptin values in the patients versus the controls (24.1±17.8 ng/ml vs 9.8±3.2 ng/ml at baseline; 33.5±21.4 ng/ml vs 11.1±3.9 ng/ml at one year), and leptin concentrations were not associated with obesity or pubertal status (Blardi et al., 2010). It is still unclear, however, if the alteration of leptin levels in autism is a primary event or a finding attributable to the disease. Plasma levels of leptin have also been investigated in patients with Rett syndrome (n=16), where it was found that leptin was significantly increased compared to healthy controls (n=16), but also did not correlate with obesity (Blardi et al., 2008), suggesting that there may be more to the actions of leptin in neurodevelopment than weight balance.

The immunomodulatory properties of leptin were first reported on a mouse model, in which obese mice were found to have impaired cell-mediated and humoral immunity, attributed to possible lack of leptin (Chandra, 1980). The epigenetic status in adulthood was shown to be directionally dependent on prenatal nutritional status (Gluckman et al., 2007) and neonatal leptin administration late in the phase of developmental plasticity was able to reverse the developmental programming in rats (Vickers et al., 2005). Mast cells also express leptin and leptin receptors, a finding implicating paracrine or autocrine immunomodulatory effects of leptin on mast cells (Taildeman et al., 2009). Locally released leptin from T lymphocytes doesn’t seem to play a major role in immunoregulation in mouse models of intestinal inflammation, suggesting other sources of leptin as critical in modulation of the inflammatory response (Fantuzzi et al., 2005). Despite evidence supporting the role of leptin in immune processes (Lago et al., 2008; Matarese et al., 2005), its precise role in inflammation remains incompletely understood.

Advertisement

7. Oxidative stress and prematurity

A variety of events associated with poor fetal growth or preterm birth are also associated with oxidative stress. These include maternal infection and inflammation that lead to increased lipid peroxidation, but more importantly to alterations in the expression of many genes associated with adverse perinatal outcomes (Ingelfinger, 2007).

Considerable evidence indicates that oxidative stress may be increased in patients with ASD, possibly due to their decreased ability to neutralize free radicals. An earlier study showed increased levels of plasma malondialdehyde, a marker of oxidative stress, (p<0.05) in the blood of mothers who delivered preterm and in the cord blood of their preterm neonates, compared to the levels in samples from term deliveries (Joshi et al., 2008). Preterm birth is associated with increased generation of reactive oxygen species (ROS), which places these infants in high risk for injury (Davis & Auten, 2010). In fact, a recent study identified an increase in the oxidative stress marker non-protein bound iron (NPBI) in the cord blood of 168 preterm newborns of gestational age 24-32 weeks (Perrone et al., 2010), suggesting that early identification of neonates at-risk is possible.

The impact of environmental oxidants in the etiology of autism is associated with brain region-specific changes in oxidative stress markers, such as 3-nitrotyrosine (3-NT) and neurotrophin-3 (NT-3), in ASD (Sajdel-Sulkowska et al., 2008; Sajdel-Sulkowska et al., 2011). Deficiencies in anti-oxidant enzymes might, in certain cases, be associated with mercury toxicity, which was shown to be tightly bound to and inactivate thioredoxin (Carvalho et al., 2008). In fact, cytosolic and mitochondrial redox imbalance was found in lymphoblastoid cells of ASD children compared to controls, an event exaggerated by exposure to thimerosal (James et al., 2009).

Several studies have suggested a link between oxidative stress and the immune response (Viora et al., 2001). Because immune cell functions are specially linked to ROS generation, their normal functioning is largely dependent on the oxidant/antioxidant balance. A strong association between oxidative stress and autoimmunity was shown in a group of 44 Egyptian autistic children, 88.64% of whom had elevated plasma F2-isoprostane (a marker of lipid peroxidation) and/or reduced glutathione peroxidase (an anti-oxidant enzyme), compared to 44 age-matched controls. Anti-neuronal antibodies were found in 54.5% of the same cohort, implying immunomodulation (Mostafa et al., 2010). Several groups have hypothesized that oxidative stress is the mechanism by which prenatal LPS affects offspring neurodevelopment (Lante et al., 2008; Paintlia et al., 2008). Potential therapies for oxidative stress and ROS-induced morbidities in the preterm infant include both enzymatic and nonenzymatic antioxidant preparations (Lee & Davis, 2011), such as the naturally-occuring flavonoids quercetin and luteolin (Cotelle, 2001; Middleton, Jr. et al., 2000). Quercetin inhibits mast cells (Kandere-Grzybowska et al., 2006), and also inhibited and reversed acute stress-induced autistic-like behavior and the associated reduced brain glutathione levels in mice (Kumar & Goyal, 2008). Luteolin can also block mast cell activation and superstimulation of activated T-cells (Kempuraj et al., 2008; Theoharides et al., 2007a). Luteolin and its structural analog diosmin prevented MIA-induced behavioral deficits in the mouse offspring by blocking the IL-6-induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) signaling pathway, both in vivoand in vitro(Parker-Athill et al., 2009). A luteolin-containing dietary supplement, Neuroprotek® was recently made available to help the body reduce brain inflammation.

Advertisement

8. Conclusion

A number of findings suggest the presence of different biological endophenotypes in ASD (Persico et al., 2008), as well as between early-onset and regressive autism, with the latter being associated with poorer outcomes in social reciprocity, verbal IQ and more gastrointestinal symptoms, according to caregiver interviews (Richler et al., 2006).

Increasing evidence indicates that perinatal immune activation, in the mother and/or the fetus, could adversely affect neurodevelopment. Moreover, mast cell activation during this period by environmental, infectious, neurohormonal and immune triggers appears to be involved in gut-blood-brain barrier disruption and subsequent brain inflammation. Reduction of stress during gestation and infancy, potential use of specific CRH receptor antagonists, as well as drugs that could prevent BBB disruption, or block brain inflammation may prove useful in at least a subgroup of infants at high risk for developing autism. These goals may be at least partly achieved by the use of mast cell blockers. Unfortunately, there are no clinically effective mast cell inhibitors, and the available disodium cromoglycate (cromolyn) has proven a weak inhibitor of human mast cells (Theoharides & Kalogeromitros, 2006). Instead, flavonoids such as luteolin are anti-inflammatory and neuroprotective (Dirscherl et al., 2010), and can inhibit mast cell activation (Asadi et al., 2010).

Advertisement

Acknowledgments

Aspects of research mentioned here were funded by Safe Minds, the National Autism Association, the Autism Research Collaborative, as well as Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA). Asimenia Angelidou and Konstantinos-Dionysios Alysandratos are recipients of scholarships for postgraduate studies from the Hellenic State Scholarships Foundation (Athens, Greece). The authors declare that they have no competing interests. TCT is the inventor of patent application US 12/534,571; US 12/861,152; US 13/009,282 covering the diagnosis and treatment of ASD.

References

  1. 1. AbbottN. J.2000Inflammatory mediators and modulation of blood-brain barrier permeability.Cell Mol Neurobiol,20131147
  2. 2. Adams-ChapmanI.2006Neurodevelopmental outcome of the late preterm infant.Clin Perinatol., 33, 4,947964
  3. 3. AngelidouA.FrancisK.VasiadiM.Alysandratos-DK.ZhangB.TheoharidesA.LykourasL.KalogeromitrosD.TheoharidesT. C.2010Neurotensin is increased in serum of young children with autistic disorder.J Neuroinflammation, 7,48 EOF
  4. 4. AngelidouA.AlysandratosK. D.AsadiS.ZhangB.FrancisK.VasiadiM.KalogeromitrosD.TheoharidesT. C.2011Brief Report: "Allergic Symptoms" in Children with Autism Spectrum Disorders. More than Meets the Eye?J Autism Dev.Disord., (Jan 6) [Ahead of print].
  5. 5. AngioniS.PetragliaF.GallinelliA.CossarizzaA.FranceschiC.MuscettolaM.GenazzaniA. D.SuricoN.GenazzaniA. R.1993Corticotropin-releasing hormone modulates cytokines release in cultured human peripheral blood mononuclear cells.Life Sci,5317351742
  6. 6. ArgyropoulouM. I.2010Brain lesions in preterm infants: initial diagnosis and follow-up.Pediatr Radiol., 40, 6,811818
  7. 7. AsadiS.ZhangB.WengZ.AngelidouA.KempurajD.AlysandratosK. D.TheoharidesT. C.2010Luteolin and thiosalicylate inhibit HgCl2 and thimerosal-induced VEGF release from human mast cells.Int J Immunopathol.Pharmacol, 23, 4,10151020
  8. 8. AshwoodP.AnthonyA.PellicerA. A.TorrenteF.Walker-SmithJ. A.WakefieldA. J.2003Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology.J Clin Immunol., 23, 6,504517
  9. 9. AshwoodP.EnstromA.KrakowiakP.Hertz-PicciottoI.HansenR. L.CroenL. A.OzonoffS.PessahI. N.de WaterJ. V.2008Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes.J Neuroimmunol.,204149153
  10. 10. AshwoodP.KwongC.HansenR.Hertz-PicciottoI.CroenL.KrakowiakP.WalkerW.PessahI. N.Van de WaterJ.2007Brief Report: Plasma leptin levels are elevated in autism: Association with early onset phenotype?J.Autism Dev.Disord., 38, 1,169175
  11. 11. AtladottirH. O.PedersenM. G.ThorsenP.MortensenP. B.DeleuranB.EatonW. W.ParnerE. T.2009Association of family history of autoimmune diseases and autism spectrum disorders.Pediatrics, 124, 2,687694
  12. 12. AtladottirH. O.ThorsenP.OstergaardL.SchendelD. E.LemckeS.AbdallahM.ParnerE. T.2010Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders.J Autism Dev.Disord., 40, 12,14231430
  13. 13. BeversdorfD. Q.ManningS. E.HillierA.AndersonS. L.NordgrenR. E.WaltersS. E.NagarajaH. N.CooleyW. C.GaelicS. E.BaumanM. L.2005Timing of prenatal stressors and autism.J Autism Dev.Disord., 35, 4,471478
  14. 14. BlankU.RiveraJ.2004The ins and outs of IgE-dependent mast-cell exocytosis.Trends Immunol,25266273
  15. 15. BlardiP.de LallaA.CeccatelliL.VanessaG.AuteriA.HayekJ.2010Variations of plasma leptin and adiponectin levels in autistic patients.Neurosci.Lett., 479, 1,5457
  16. 16. deBlardiP.LallaA.D’AmbrogioT. G. V. L. C. A. A.J. H.2008Long-term plasma levels of leptin and adiponectin in Rett Syndrome. Clin Endocrinol. (Oxf), 70, 5,706709
  17. 17. BoksaP.2010Effects of prenatal infection on brain development and behavior: a review of findings from animal models.Brain Behav.Immun., 24, 6,881897
  18. 18. BraunschweigD.AshwoodP.KrakowiakP.Hertz-PicciottoI.HansenR.CroenL. A.PessahI. N.Van de WaterJ.2008Autism: maternally derived antibodies specific for fetal brain proteins.NeuroToxicology, 29, 2,226231
  19. 19. BrimacombeM.MingX.LamendolaM.2007Prenatal and birth complications in autism.Matern.Child Health J, 11, 1,7379
  20. 20. BuchmayerS.JohanssonS.JohanssonA.HultmanC. M.SparenP.CnattingiusS.2009Can association between preterm birth and autism be explained by maternal or neonatal morbidity?Pediatrics, 124, 5,e817e825
  21. 21. BuieT.CampbellD. B.FuchsG. J.IIIFurutaG. T.LevyJ.VandewaterJ.WhitakerA. H.AtkinsD.BaumanM. L.BeaudetA. L.CarrE. G.GershonM. D.HymanS. L.JirapinyoP.JyonouchiH.KoorosK.KushakR.LevittP.LevyS. E.LewisJ. D.MurrayK. F.NatowiczM. R.SabraA.WershilB. K.WestonS. C.ZeltzerL.WinterH.2010Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 125, Suppl 1:S118
  22. 22. CabanlitM.WillsS.GoinesP.AshwoodP.Van de WaterJ.2007Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder.Ann.N Y.Acad.Sci.,110792103
  23. 23. CampbellE. A.LintonE. A.WolfeC. D.ScraggsP. R.JonesM. T.LowryP. J.1987Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition.J Clin Endocrinol.Metab, 64, 5,10541059
  24. 24. CaoJ.PapadopoulouN.KempurajD.BoucherW. S.SugimotoK.CetruloC. L.TheoharidesT. C.2005Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor.J Immunol,17476657675
  25. 25. CarvalhoC. M.ChewE. H.HashemyS. I.LuJ.HolmgrenA.2008Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity.J Biol.Chem., 283, 18,1191311923
  26. 26. CastagliuoloI.LeemanS. E.Bartolac-SukiE.NikulassonS.QiuB.CarrawayR. E.PothoulakisC.1996A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats.Proc Natl Acad Sci USA,931261112615
  27. 27. ChandlerN.JacobsonS.ConnollyR.EspositoP.TheoharidesT. C.2002Acute stress shortens the time of onset of experimental allergic encephalomyelitis (EAE) in SJL/J mice.Brain Behav Immun,16757763
  28. 28. ChandraR. K.1980Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice.Am.J Clin Nutr., 33, 1,1316
  29. 29. Cheslack-PostavaK.LiuK.BearmanP. S.2011Closely Spaced Pregnancies Are Associated With Increased Odds of Autism in California Sibling Births.Pediatrics,
  30. 30. ChessS.1977Follow-up report on autism in congenital rubella.J Autism Child Schizophr., 127, 2,246253
  31. 31. ChezM. G.DowlingT.PatelP. B.KhannaP.KominskyM.2007Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children.Pediatr.Neurol., 36, 6,361365
  32. 32. ChrousosG. P.1995The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.N Engl J Med,33213511362
  33. 33. ConsidineR. V.SinhaM. K.HeimanM. L.KriauciunasA.StephensT. W.NyceM. R.OhannesianJ. P.MarcoC. C.Mc KeeL. J.BauerT. L.1996Serum immunoreactive-leptin concentrations in normal-weight and obese humans.N.Engl.J Med., 334, 5,292295
  34. 34. ContiP.PangX.BoucherW.LetourneauR.RealeM.BarbacaneR. C.ThibaultJ.TheoharidesT. C.1997Impact of Rantes and MCP-1 chemokines onin vivobasophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood,8941204127
  35. 35. CorbettB. A.SchuppC. W.LevineS.MendozaS.2009Comparing cortisol, stress, and sensory sensitivity in children with autism.Autism Res., 2, 1,3949
  36. 36. CorbettB. A.SchuppC. W.SimonD.RyanN.MendozaS.2010Elevated cortisol during play is associated with age and social engagement in children with autism.Mol.Autism, 1, 1,13
  37. 37. CotelleN.2001Role of flavonoids in oxidative stress.Curr.Top.Med.Chem., 1, 6,569590
  38. 38. CroenL. A.BraunschweigD.HaapanenL.YoshidaC. K.FiremanB.GretherJ. K.KharraziM.HansenR. L.AshwoodP.Van de WaterJ.2008Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study.Biological Psychiatry, 64, 7,583588
  39. 39. CroenL. A.GretherJ. K.YoshidaC. K.OdouliR.Van de WaterJ.2005Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study.Arch.Pediatr.Adolesc.Med., 159, 2,151157
  40. 40. DardenoT. A.ChouS. H.MoonH. S.ChamberlandJ. P.FiorenzaC. G.MantzorosC. S.2010Leptin in human physiology and therapeutics.Front Neuroendocrinol., 31, 3,377393
  41. 41. DavisJ. M.AutenR. L.2010Maturation of the antioxidant system and the effects on preterm birth.Semin.Fetal Neonatal Med., 15, 4,191195
  42. 42. DethR.MuratoreC.BenzecryJ.Power-CharnitskyV. A.WalyM.2008How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis.NeuroToxicology, 29, 1,190201
  43. 43. DirscherlK.KarlstetterM.EbertS.KrausD.HlawatschJ.WalczakY.MoehleC.FuchshoferR.LangmannT.2010Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype.J Neuroinflammation., 7, 1,3
  44. 44. DoddsL.FellD. B.SheaS.ArmsonB. A.AllenA. C.BrysonS.2011The Role of Prenatal, Obstetric and Neonatal Factors in the Development of Autism.J Autism Dev.Disord., 41, 7,891902
  45. 45. DommerguesM. A.PatkaiJ.RenauldJ. C.EvrardP.GressensP.2000Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium.Ann.Neurol., 47, 1,5463
  46. 46. DonelanJ.BoucherW.PapadopoulouN.LytinasM.PapaliodisD.TheoharidesT. C.2006Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process.Proc Natl Acad Sci USA,10377597764
  47. 47. DrubeS.HeinkS.WalterS.LohnT.GrusserM.GerbauletA.BerodL.SchonsJ.DudeckA.FreitagJ.GrothaS.ReichD.RudeschkoO.NorgauerJ.HartmannK.RoersA.KamradtT.2010The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells.Blood, 115, 19,38993906
  48. 48. DubickeA.FranssonE.CentiniG.AnderssonE.BystromB.MalmstromA.PetragliaF.Sverremark-EkstromE.Ekman-OrdebergG.2010Pro-inflammatory and anti-inflammatory cytokines in human preterm and term cervical ripening.J Reprod.Immunol, 84, 2,176185
  49. 49. DunnS. J.GreenbergH. B.WardR. L.NakagomiO.BurnsJ. W.VoP. T.PaxK. A.DasM.GowdaK.RaoC. D.1993Serotypic and genotypic characterization of human serotype 10 rotaviruses from asymptomatic neonates.J Clin Microbiol., 31, 1,165169
  50. 50. DurkinM. S.MaennerM. J.MeaneyF. J.LevyS. E.Di GuiseppiC.NicholasJ. S.KirbyR. S.Pinto-MartinJ. A.SchieveL. A.2010Socioeconomic inequality in the prevalence of autism spectrum disorder: evidence from a U.S. cross-sectional study.PLoS.ONE., 5, 7,e11551
  51. 51. EhningerD.SanoY.de VriesP. J.DiesK.FranzD.GeschwindD. H.KaurM.LeeY. S.LiW.LoweJ. K.NakagawaJ. A.SahinM.SmithK.WhittemoreV.SilvaA. J.2010Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice.Mol.Psychiatry, (Nov 16) [Ahead of print].
  52. 52. EnstromA. M.Van de WaterJ. A.AshwoodP.2009Autoimmunity in autism.Curr.Opin.Investig.Drugs, 10, 5,463473
  53. 53. EspositoP.ChandlerN.Kandere-GrzybowskaK.BasuS.JacobsonS.ConnollyR.TutorD.TheoharidesT. C.2002Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress.J Pharmacol Exp Ther,30310611066
  54. 54. EspositoP.GheorgheD.KandereK.PangX.ConallyR.JacobsonS.TheoharidesT. C.2001Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.Brain Res,888117127
  55. 55. FantuzziG.SennelloJ. A.BatraA.FedkeI.LehrH. A.ZeitzM.SiegmundB.2005Defining the role of T cell-derived leptin in the modulation of hepatic or intestinal inflammation in mice.Clin Exp.Immunol, 142, 1,3138
  56. 56. FombonneE.2009Epidemiology of pervasive developmental disorders.Pediatric Research, 65, 6,591598
  57. 57. ForbesE. E.GroschwitzK.AboniaJ. P.BrandtE. B.CohenE.BlanchardC.AhrensR.SeiduL.Mc KenzieA.StraitR.FinkelmanF. D.FosterP. S.MatthaeiK. I.RothenbergM. E.HoganS. P.2008IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity.Journal of Experimental Medicine, 205, 4,897913
  58. 58. GalliS. J.KalesnikoffJ.GrimbaldestonM. A.PiliponskyA. M.WilliamsC. M.TsaiM.2005Mast cells as "tunable" effector and immunoregulatory cells: recent advances.Annu Rev Immunol,23749786
  59. 59. GardenerH.SpiegelmanD.BukaS. L.2009Prenatal risk factors for autism: comprehensive meta-analysis.Br.J Psychiatry, 195, 1,714
  60. 60. GebhardtT.LorentzA.DetmerF.TrautweinC.BektasH.MannsM. P.BischoffS. C.2005Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1.Gut, 54, 7,928934
  61. 61. GillottA.StandenP. J.2007Levels of anxiety and sources of stress in adults with autism.J.Intellect.Disabil., 11, 4,359370
  62. 62. GirardS.TremblayL.LepageM.SebireG.2010IL-1 receptor antagonist protects against placental and neurodevelopmental defects induced by maternal inflammation.J Immunol, 184, 7,39974005
  63. 63. GiuliviC.ZhangY. F.Omanska-KlusekA.Ross-IntaC.WongS.Hertz-PicciottoI.TassoneF.PessahI. N.2010Mitochondrial dysfunction in autism.JAMA, 304, 21,23892396
  64. 64. GlassonE. J.BowerC.PettersonB.de KlerkN.ChaneyG.HallmayerJ. F.2004Perinatal factors and the development of autism: a population study.Arch.Gen.Psychiatry, 61, 6,618627
  65. 65. GluckmanP. D.LillycropK. A.VickersM. H.PleasantsA. B.PhillipsE. S.BeedleA. S.BurdgeG. C.HansonM. A.2007Metabolic plasticity during mammalian development is directionally dependent on early nutritional status.Proc Natl Acad Sci U S A, 104, 31,1279612800
  66. 66. GoinesP.Van de WaterJ.2010The immune system’s role in the biology of autism.Curr.Opin.Neurol., 23, 2,111117
  67. 67. GrammatopoulosD. K.2008Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma.Journal of Neuroendocrinology, 20, 4,432438
  68. 68. GrandjeanP.LandriganP. J.2006Developmental neurotoxicity of industrial chemicals.Lancet, 368, 9553,21672178
  69. 69. Hauguel-deMouzon. S.LepercqJ.CatalanoP.2006The known and unknown of leptin in pregnancy.Am.J Obstet.Gynecol., 194, 6,15371545
  70. 70. HerbertM. R.2010Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders.Curr.Opin.Neurol., 23, 2,103110
  71. 71. Hertz-PicciottoI.ParkH. Y.DostalM.KocanA.TrnovecT.SramR.2008Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development.Basic Clin.Pharmacol.Toxicol., 102, 2,146154
  72. 72. IngelfingerJ. R.2007Prematurity and the legacy of intrauterine stress.N.Engl.J Med., 356, 20,20932095
  73. 73. ItoN.SugawaraK.BodoE.TakigawaM.van BeekN.ItoT.PausR.2010Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme.J Invest Dermatol., 130, 4,9951004
  74. 74. JamesS. J.RoseS.MelnykS.JerniganS.BlossomS.PavlivO.GsylorD. W.2009Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism.FASEB, 23(8)23742383
  75. 75. JohnsonC. P.MyersS. M.2007Identification and evaluation of children with autism spectrum disorders.Pediatrics, 120, 5,11831215
  76. 76. JohnsonS.HollisC.KochharP.HennessyE.WolkeD.MarlowN.2010Autism spectrum disorders in extremely preterm children.J Pediatr., 156, 4,525531
  77. 77. JohnsonS.MarlowN.2011Preterm Birth and Childhood Psychiatric Disorders.Pediatric Research, (May) [Ahead of print]., 69, 5 Pt 2,11R18R
  78. 78. JoshiS. R.MehendaleS. S.DangatK. D.KilariA. S.YadavH. R.TaralekarV. S.2008High maternal plasma antioxidant concentrations associated with preterm delivery.Ann.Nutr.Metab, 53, 3-4,276282
  79. 79. KaindlA. M.FavraisG.GressensP.2009Molecular mechanisms involved in injury to the preterm brain.J Child Neurol., 24, 9,11121118
  80. 80. KalantaridouS.MakrigiannakisA.ZoumakisE.ChrousosG. P.2007Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications.Front Biosci.,12572580
  81. 81. Kandere-GrzybowskaK.LetourneauR.KempurajD.DonelanJ.PoplawskiS.BoucherW.AthanassiouA.TheoharidesT. C.2003IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells.J Immunol, 171, 9,48304836
  82. 82. Kandere-GrzybowskaK.KempurajD.CaoJ.CetruloC. L.TheoharidesT. C.2006Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin.Br J Pharmacol,148208215
  83. 83. KaralisK.LouisJ. M.BaeD.HilderbrandH.MajzoubJ. A.1997CRH and the immune system.J Neuroimmunol,72131136
  84. 84. KeilA.DanielsJ. L.ForssenU.HultmanC.CnattingiusS.SoderbergK. C.FeychtingM.SparenP.2010Parental autoimmune diseases associated with autism spectrum disorders in offspring.Epidemiology, 21, 6,805808
  85. 85. KempurajD.AsadiS.ZhangB.ManolaA.HoganJ.PetersonE.TheoharidesT. C.2010Mercury induces inflammatory mediator release from human mast cells.J Neuroinflammation, 7, 1,20
  86. 86. KempurajD.PapadopoulouN. G.LytinasM.HuangM.Kandere-GrzybowskaK.MadhappanB.BoucherW.ChristodoulouS.AthanassiouA.TheoharidesT. C.2004Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells.Endocrinology,1454348
  87. 87. KempurajD.TagenM.IliopoulouB. P.ClemonsA.VasiadiM.BoucherW.HouseM.WolfergA.TheoharidesT. C.2008Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells.Br J Pharmacol,15510761084
  88. 88. KinneyD. K.MunirK. M.CrowleyD. J.MillerA. M.2008Prenatal stress and risk for autism.Neurosci.Biobehav.Rev., 32, 8,15191532
  89. 89. KleinmanJ. M.RobinsD. L.VentolaP. E.PandeyJ.BoorsteinH. C.EsserE. L.WilsonL. B.RosenthalM. A.SuteraS.VerbalisA. D.BartonM.HodgsonS.GreenJ.Dumont-MathieuT.VolkmarF.ChawarskaK.KlinA.FeinD.2008The modified checklist for autism in toddlers: a follow-up study investigating the early detection of autism spectrum disorders.J Autism Dev.Disord., 38, 5,827839
  90. 90. KoganM. D.BlumbergS. J.SchieveL. A.BoyleC. A.PerrinJ. M.GhandourR. M.SinghG. K.StricklandB. B.TrevathanE.van DyckP. C.2009Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007.Pediatrics, 5, 124,13951403
  91. 91. KraftS.KinetJ. P.2007New developments in FcepsilonRI regulation, function and inhibition.Nat Rev.Immunol, 7, 5,365378
  92. 92. KubanK. C.O’SheaT. M.AllredE. N.Tager-FlusbergH.GoldsteinD. J.LevitonA.2009Positive screening on the Modified Checklist for Autism in Toddlers (M-CHAT) in extremely low gestational age newborns.Journal of Pediatrics, 154, 4,535540
  93. 93. KulkaM.AlexopoulouL.FlavellR. A.MetcalfeD. D.2004Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3.J Allergy Clin.Immunol, 114, 1,174182
  94. 94. KumarA.GoyalR.2008Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice.J Med Food, 11, 3,469473
  95. 95. KwonO.LeeE.MoonT. C.JungH.LinC. X.NamK. S.BaekS. H.MinH. K.ChangH. W.2002Expression of cyclooxygenase-2 and pro-inflammatory cytokines induced by 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB 153) in human mast cells requires NF-kappa B activation.Biol.Pharm.Bull., 25, 9,11651168
  96. 96. LagoR.GomezR.LagoF.Gomez-ReinoJ.GualilloO.2008Leptin beyond body weight regulation--current concepts concerning its role in immune function and inflammation.Cell Immunol, 252, 1-2,139145
  97. 97. LanteF.MeunierJ.GuiramandJ.De JesusFerreira. M. C.CambonieG.AimarR.Cohen-SolalC.MauriceT.VignesM.BarbanelG.2008Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation.Hippocampus, 18, 6,602609
  98. 98. LarssonH. J.EatonW. W.MadsenK. M.VestergaardM.OlesenA. V.AgerboE.SchendelD.ThorsenP.MortensenP. B.2005Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status.Am.J Epidemiol., 161, 10,916925
  99. 99. LeeJ. W.DavisJ. M.2011Future applications of antioxidants in premature infants.Curr.Opin.Pediatr., 23, 2,161166
  100. 100. LeeJ. Y.HuertaP. T.ZhangJ.KowalC.BertiniE.VolpeB. T.DiamondB.2009Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus.Nat.Med., 15, 1,9196
  101. 101. LevyS. E.MandellD. S.SchultzR. T.2009Autism.Lancet, 374, 9701,16271638
  102. 102. LiX.ChauhanA.SheikhA. M.PatilS.ChauhanV.LiX. M.JiL.BrownT.MalikM.2009Elevated immune response in the brain of autistic patients.J.Neuroimmunol., 207, 1-2,111116
  103. 103. LibbeyJ. E.SweetenT. L.Mc MahonW. M.FujinamiR. S.2005Autistic disorder and viral infections.J Neurovirol., 11, 1,110
  104. 104. LimperopoulosC.2009Autism spectrum disorders in survivors of extreme prematurity.Clin Perinatol., 36, 4,791805vi.
  105. 105. LimperopoulosC.BassanH.GauvreauK.RobertsonR. L.JrSullivanN. R.BensonC. B.AveryL.StewartJ.SoulJ. S.RingerS. A.VolpeJ. J.du PlessisA. J.2007Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors?Pediatrics, 120, 3,584593
  106. 106. LimperopoulosC.BassanH.SullivanN. R.SoulJ. S.RobertsonR. L.JrMooreM.RingerS. A.VolpeJ. J.duPlessis. A. J.2008Positive screening for autism in ex-preterm infants: prevalence and risk factors.Pediatrics, 121, 4,758765
  107. 107. LinC. Y.ChangY. C.WangS. T.LeeT. Y.LinC. F.HuangC. C.2010Altered inflammatory responses in preterm children with cerebral palsy.Ann.Neurol., 68, 2,204212
  108. 108. MacDorman. M. F.DeclercqE.ZhangJ.2010Obstetrical intervention and the singleton preterm birth rate in the United States from 1991-2006.Am J Public Health, 100, 11,22412247
  109. 109. MaimburgR. D.VaethM.2006Perinatal risk factors and infantile autism.Acta Psychiatr.Scand., 114, 4,257264
  110. 110. MakrigiannakisA.SemmlerM.BrieseV.EckerleH.MinasV.MylonasI.FrieseK.JeschkeU.2007Maternal serum corticotropin-releasing hormone and ACTH levels as predictive markers of premature labor.Int.J.Gynaecol.Obstet., 97, 2,115119
  111. 111. MartinJ. A.2011Preterm Births--- United States, 2007.MMWR Surveill Summ., 60, SU-1,7879
  112. 112. MatareseG.MoschosS.MantzorosC. S.2005Leptin in immunology.J Immunol, 174, 6,31373142
  113. 113. MatsonJ. L.KozlowskiA. M.2010Autistic regression. Res Autism Spectr Disord,4340345
  114. 114. MiddletonE.JrKandaswamiC.TheoharidesT. C.2000The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer.Pharmacol Rev,52673751
  115. 115. MilesJ. H.2011Autism spectrum disorders-A genetics review.Genet.Med,134278294
  116. 116. MinagarA.AlexanderJ. S.2003Blood-brain barrier disruption in multiple sclerosis.Mult.Scler., 9, 6,540549
  117. 117. MoneyJ.BobrowN. A.ClarkeF. C.1971Autism and autoimmune disease: a family study.J Autism Child Schizophr., 1, 2,146160
  118. 118. MostafaG. A.El -HadidiE. S.HewediD. H.AbdouM. M.2010Oxidative stress in Egyptian children with autism: relation to autoimmunity.J Neuroimmunol., 219, 1-2,114118
  119. 119. MostafaG. A.El -SayedZ. A.El -AzizM. M.El -SayedM. F.2008Serum anti-myelin-associated glycoprotein antibodies in Egyptian autistic children.J Child Neurol, 23, 12,14131418
  120. 120. MostafaG. A.KitchenerN.2009Serum anti-nuclear antibodies as a marker of autoimmunity in Egyptian autistic children.Pediatr Neurol, 40, 2,107112
  121. 121. O’MahonyS. M.MarchesiJ. R.ScullyP.CodlingC.CeolhoA. M.QuigleyE. M.CryanJ. F.DinanT. G.2009Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses.Biological Psychiatry, 65, 3,263267
  122. 122. OkumuraA.YamamotoT.KidokoroH.KatoT.KubotaT.ShojiH.SatoH.ShimojimaK.ShimizuT.2010Altered gene expression in umbilical cord mononuclear cells in preterm infants with periventricular leukomalacia.Early Hum.Dev., 86, 10,665667
  123. 123. PaintliaM. K.PaintliaA. S.ContrerasM. A.SinghI.SinghA. K.2008Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine.Exp.Neurol., 210, 2,560576
  124. 124. PalmieriL.PersicoA. M.2010Mitochondrial dysfunction in autism spectrum disorders: Cause or effect?Biochim.Biophys.Acta, 1797, 6-7,11301137
  125. 125. Parker-AthillE.LuoD.BaileyA.GiuntaB.TianJ.ShytleR. D.MurphyT.LegradiG.TanJ.2009Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism.J Neuroimmunol., 217, 1-2,2027
  126. 126. PerroneS.TatarannoM. L.NegroS.LonginiM.MarzocchiB.ProiettiF.IacoponiF.CapitaniS.BuonocoreG.2010Early identification of the risk for free radical-related diseases in preterm newborns.Early Hum.Dev., 86, 4,241244
  127. 127. PersicoA. M.SaccoR.CuratoloP.ManziB.LentiC.SaccaniM.MiliterniR.BravaccioC.EliaA.2008Isolation of principal components in autistic disorder symptomatology and their association with biological endophenotypes.Proc.Society for Neuroscience, Washington DC, Abstract #446.20.
  128. 128. PetragliaF.GarutiG. C.De RamundoB.AngioniS.GenazzaniA. R.BilezikjianL. M.1990Mechanism of action of interleukin-1 beta in increasing corticotropin-releasing factor and adrenocorticotropin hormone release from cultured human placental cells.Am.J Obstet.Gynecol., 163, 4 Pt 1,13071312
  129. 129. RichlerJ.LuysterR.RisiS.HsuW. L.DawsonG.BernierR.DunnM.HepburnS.HymanS. L.Mc MahonW. M.Goudie-NiceJ.MinshewN.RogersS.SigmanM.SpenceM. A.GoldbergW. A.Tager-FlusbergH.VolkmarF. R.LordC.2006Is there a ‘regressive phenotype’ of Autism Spectrum Disorder associated with the measles-mumps-rubella vaccine? A CPEA Study.J Autism Dev.Disord., 36, 3,299316
  130. 130. RoviraN.AlarconA.IriondoM.IbanezM.PooP.CusiV.AgutT.PertierraA.KrauelX.2011Impact of histological chorioamnionitis, funisitis and clinical chorioamnionitis on neurodevelopmental outcome of preterm infants.Early Hum.Dev,84253257
  131. 131. Sajdel-SulkowskaE. M.LipinskiB.WindomH.AudhyaT.Mc GinnisW.2008Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels.AM J Biochem Biotechnol,47384
  132. 132. Sajdel-SulkowskaE. M.XuM.Mc GinnisW.KoibuchiN.2011Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD).Cerebellum, 10, 1,4348
  133. 133. SaresellaM.MarventanoI.GueriniF. R.MancusoR.CeresaL.ZanzotteraM.RusconiB.MaggioniE.TinelliC.ClericiM.2009An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children.Biological Psychiatry, 66, 10,978984
  134. 134. SchroederJ. T.Kagey-SobotkaA.MacGlashan. D. W.LichtensteinL. M.1995The interaction of cytokines with human basophils and mast cells.International Archives of Allergy and Immunology,1077981
  135. 135. SchwartzL. B.1987Mediators of human mast cells and human mast cell subsets.Ann Allergy,58226235
  136. 136. SerafinW. E.AustenK. F.1987Mediators of immediate hypersensitivity reactions.N Engl J Med,3173034
  137. 137. SingerH. S.MorrisC. M.GauseC. D.GillinP. K.CrawfordS.ZimmermanA. W.2008Antibodies against fetal brain in sera of mothers with autistic children.J Neuroimmunol., 194, 1-2,165172
  138. 138. SingerH. S.MorrisC. M.WilliamsP. N.YoonD. Y.HongJ. J.ZimmermanA. W.2006Antibrain antibodies in children with autism and their unaffected siblings.J Neuroimmunol., 178, 1-2,149155
  139. 139. SinghV. K.RivasW. H.2004Prevalence of serum antibodies to caudate nucleus in autistic children.Neurosci.Lett., 355, 1-2,5356
  140. 140. SinghV. K.WarrenR.AverettR.GhaziuddinM.1997Circulating autoantibodies to neuronal and glial filament proteins in autism.Pediatr.Neurol., 17, 1,8890
  141. 141. SkofitschG.ZamirN.HelkeC. J.SavittJ. M.JacobowitzD. M.1985Corticotropin-releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides.Peptides,6307318
  142. 142. SlominskiA.WortsmanJ.PisarchikA.ZbytekB.LintonE. A.MazurkiewiczJ. E.WeiE. T.2001Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors.FASEB J,1516781693
  143. 143. SlominskiA.ZbytekB.ZmijewskiM.SlominskiR. M.KauserS.WortsmanJ.TobinD. J.2006Corticotropin releasing hormone and the skin.Front Biosci,1122302248
  144. 144. SmalleyS. L.1998Autism and tuberous sclerosis.J Autism Dev.Disord., 28, 5,407414
  145. 145. SmithS. E.LiJ.GarbettK.MirnicsK.PattersonP. H.2007Maternal immune activation alters fetal brain development through interleukin-6.Journal of Neuroscience, 27, 40,1069510702
  146. 146. SnegovskikhV. V.SchatzF.ArcuriF.TotiP.KayisliU. A.MurkW.GuoyangLuo.LockwoodC. J.NorwitzE. R.2009Intra-amniotic infection upregulates decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and-2 expression: implications for infection-related preterm birth.Reprod.Sci., 16, 8,767780
  147. 147. SoderholmJ. D.YatesD. A.GareauM. G.YangP. C.MacQueen. G.PerdueM. H.2002Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress.Am.J Physiol Gastrointest.Liver Physiol, 283, 6,G1257G1263
  148. 148. SoonD.AltmannD. R.FernandoK. T.GiovannoniG.BarkhofF.PolmanC. H.O’ConnorP.GrayB.PanzaraM.MillerD. H.2007A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.J Neurol., 254, 3,306314
  149. 149. SteinD.WeizmanA.RingA.BarakY.2006Obstetric complications in individuals diagnosed with autism and in healthy controls.Comprehensive Psychiatry, 47, 1,6975
  150. 150. StoneK. D.PrussinC.MetcalfeD. D.2010IgE, mast cells, basophils, and eosinophils.The Journal of Allergy and Clinical Immunology, 125, 2 Suppl 2,S73S80
  151. 151. StoneL. A.SmithM. E.AlbertP. S.BashC. N.MaloniH.FrankJ. A.Mc FarlandH. F.1995Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age.Neurology,4511221126
  152. 152. SupajaturaV.UshioH.NakaoA.AkiraS.OkumuraK.RaC.OgawaH.2002Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity.J Clin Invest,10913511359
  153. 153. TaildemanJ.Perez-NovoC. A.RottiersI.FerdinandeL.WaeytensA.De ColvenaerV.BachertC.DemetterP.WaelputW.BraetK.CuvelierC. A.2009Human mast cells express leptin and leptin receptors.Histochem.Cell Biol., 131, 6,703711
  154. 154. TeunisM. A.HeijnenC. J.SluyterF.BakkerJ. M.Van DamA. M.HofM.CoolsA. R.KavelaarsA.2002Maternal deprivation of rat pups increases clinical symptoms of experimental autoimmune encephalomyelitis at adult age.J.Neuroimmunol., 133, 1-2,3038
  155. 155. ThaxtonJ. E.NeversT. A.SharmaS.2010TLR-mediated preterm birth in response to pathogenic agents.Infect.Dis.Obstet.Gynecol., 2010, pii: 378472.
  156. 156. TheoharidesT. C.2009Autism spectrum disorders and mastocytosis.Int J Immunopathol Pharmacol, 22, 4,859865
  157. 157. TheoharidesT. C.AngelidouA.AlysandratosK. D.ZhangB.AsadiS.FrancisK.ToniatoE.KalogeromitrosD.2011Mast cell activation and autism.Biochim.Biophys.Acta, (Dec 23) [Ahead of print].
  158. 158. TheoharidesT. C.CochraneD. E.2004Critical role of mast cells in inflammatory diseases and the effect of acute stress.J Neuroimmunol,146112
  159. 159. TheoharidesT. C.DonelanJ. M.PapadopoulouN.CaoJ.KempurajD.ContiP.2004Mast cells as targets of corticotropin-releasing factor and related peptides.Trends Pharmacol Sci,25563568
  160. 160. TheoharidesT. C.DoyleR.2008Autism, gut-blood-brain barrier and mast cells.J Clin Psychopharmacol, 28, 5,479483
  161. 161. TheoharidesT. C.DoyleR.FrancisK.ContiP.KalogeromitrosD.2008Novel therapeutic targets for autism.Trends Pharmacol Sci., 29, 8,375382
  162. 162. TheoharidesT. C.KalogeromitrosD.2006The critical role of mast cell in allergy and inflammation.Ann NY Acad Sci,10887899
  163. 163. TheoharidesT. C.KempurajD.IliopoulouB. P.2007aMast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis.Advances in Experimental Medicine and Biology,601423430
  164. 164. TheoharidesT. C.KempurajD.TagenM.ContiP.KalogeromitrosD.2007bDifferential release of mast cell mediators and the pathogenesis of inflammation.Immunol Rev,2176578
  165. 165. TheoharidesT. C.KonstantinidouA.2007Corticotropin-releasing hormone and the blood-brain-barrier.Front Biosci,1216151628
  166. 166. TheoharidesT. C.ZhangB.KempurajD.TagenM.VasiadiM.AngelidouA.AlysandratosK. D.KalogeromitrosD.AsadiS.StavrianeasN.PetersonE.LeemanS.ContiP.2010IL-33 augments substance P-induced VEGFsecretion from human mast cells and is increased in psoriatic skin.Proc Natl Acad Sci U S A, 107, 9,44484453
  167. 167. TorigoeC.GoldsteinB.WofsyC.MetzgerH.1997Shuttling of initiating kinase between discrete aggregates of the high affinity receptor for IgE regulates the cellular response.Proc.Natl.Acad.Sci.U.S.A, 94, 4,13721377
  168. 168. TorrenteF.AshwoodP.DayR.MachadoN.FurlanoR. I.AnthonyA.DaviesS. E.WakefieldA. J.ThomsonM. A.Walker-SmithJ. A.MurchS. H.2002Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism.Mol.Psychiatry, 7, 4,375382
  169. 169. TorricelliM.NovembriR.BloiseE.De BonisM.ChallisJ. R.PetragliaF.2011Changes in placental CRH, urocortins, and CRH-receptor mRNA expression associated with preterm delivery and chorioamnionitis.J Clin Endocrinol.Metab, 96, 2,534540
  170. 170. VaradaradjalouS.FegerF.ThieblemontN.HamoudaN. B.PleauJ. M.DyM.ArockM.2003Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells.Eur J Immunol,33899906
  171. 171. VargasD. L.NascimbeneC.KrishnanC.ZimmermanA. W.PardoC. A.2005Neuroglial activation and neuroinflammation in the brain of patients with autism.Ann.Neurol., 57, 1,6781
  172. 172. VickersM. H.GluckmanP. D.CovenyA. H.HofmanP. L.CutfieldW. S.GertlerA.BreierB. H.HarrisM.2005Neonatal leptin treatment reverses developmental programming.Endocrinology, 146, 10,42114216
  173. 173. VioraM.QuarantaM. G.StrafaceE.VariR.MasellaR.MalorniW.2001Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine.Immunology, 104, 4,431438
  174. 174. VojdaniA.CampbellA. W.AnyanwuE.KashanianA.BockK.VojdaniE.2002Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A.J Neuroimmunol., 129, 1-2,168177
  175. 175. VolpeJ. J.2009The encephalopathy of prematurity--brain injury and impaired brain development inextricably intertwined.Semin.Pediatr Neurol, 16, 4,167178
  176. 176. WarrenW. B.PatrickS. L.GolandR. S.1992Elevated maternal plasma corticotropin-releasing hormone levels in pregnancies complicated by preterm labor.Am J Obstet Gynecol,1661198204
  177. 177. WeaverI. C.CervoniN.ChampagneF. A.D’AlessioA. C.SharmaS.SecklJ. R.DymovS.SzyfM.MeaneyM. J.2004Epigenetic programming by maternal behavior.Nat.Neurosci., 7, 8,847854
  178. 178. WeissL. A.ArkingD. E.DalyM. J.ChakravartiA.2009A genome-wide linkage and association scan reveals novel loci for autism.Nature, 461, 7265,802808
  179. 179. WilkersonD. S.VolpeA. G.DeanR. S.TitusJ. B.2002Perinatal complications as predictors of infantile autism.Int J Neurosci., 112, 9,10851098
  180. 180. WillsS.CabanlitM.BennettJ.AshwoodP.AmaralD.Van de WaterJ.2007Autoantibodies in autism spectrum disorders (ASD).Ann.N.Y.Acad.Sci.,11077991
  181. 181. WillsS.CabanlitM.BennettJ.AshwoodP.AmaralD. G.Van de WaterJ.2008Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders.Brain Behav.Immun.,236474
  182. 182. YasuokaS.KawanokuchiJ.ParajuliB.JinS.DoiY.NodaM.SonobeY.TakeuchiH.MizunoT.SuzumuraA.2011Production and functions of IL-33 in the central nervous system.Brain Res, 1385,817
  183. 183. YoungH. A.GeierD. A.GeierM. R.2008Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.J Neurol Sci, 271, 1-2,110118
  184. 184. ZappellaM.2010Autistic regression with and without EEG abnormalities followed by favourable outcome.Brain Dev., 32, 9,739745
  185. 185. ZhangB.AngelidouA.AlysandratosK. D.VasiadiM.FrancisK.AsadiS.TheoharidesA.Siderik.LykourasL.KalogeromitrosD.TheoharidesT. C.2010Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children.J Neuroinflammation, 7, 1,80
  186. 186. ZhangT. Y.MeaneyM. J.2010Epigenetics and the environmental regulation of the genome and its function.Annu.Rev Psychol.,614393
  187. 187. ZimmermanA. W.ConnorsS. L.MattesonK. J.LeeL. C.SingerH. S.CastanedaJ. A.PearceD. A.2007Maternal antibrain antibodies in autism.Brain Behav.Immun., 21, 3,351357

Notes

Written By

Theoharis Theoharides, Asimenia Angelidou, Konstantinos-Dionysios Alysandratos, Shahrzad Asadi, Konstantinos Francis, Lefteris Lykouras and Dimitrios Kalogeromitros

Submitted: October 20th, 2010 Reviewed: May 9th, 2011 Published: August 17th, 2011